Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aeterna Zentaris Inc. AEZS
$3.00
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
14470522.00000000
-
week52high
8.75
-
week52low
2.32
-
Revenue
5640000
-
P/E TTM
0
-
Beta
1.72065900
-
EPS
-4.61000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 30 мар 2022 г. |
| HC Wainwright & Co. | Buy | 25 окт 2021 г. | |
| Canaccord Genuity | Buy | Hold | 09 ноя 2015 г. |
| H.C. Wainwright | Buy | Neutral | 14 апр 2015 г. |
| H.C. Wainwright | Buy | 17 июл 2014 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
23 мар 2023 г. в 10:40
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
07 февр 2023 г. в 11:19
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
GlobeNewsWire
10 янв 2023 г. в 08:05
Live video webcast on Thursday , January 19 th at 3 :00 PM ET